ReviewPharmaceuticals (Basel, Switzerland)2020
Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review.
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Oral therapeutic interventions for central serous chorioretinopathy: A systematic review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Pooled it
- Interventions for central serous chorioretinopathy: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Treatment of Central Serous Chorioretinopathy With Topical Difluprednate: A Literature Review.Cureus · 2026Review
- Article
- Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy.International journal of ophthalmology · 2025Article
- Dysthyroid optic neuropathy treated with tocilizumab.Endocrinology, diabetes & metabolism case reports · 2025Article
- Early versus delayed photodynamic therapy for chronic central serous chorioretinopathy.International ophthalmology · 2023Article
- Real-world practice patterns of eplerenone use for central serous chorioretinopathy.International journal of retina and vitreous · 2023Article
- Three-Year Follow-Up Detecting Choroidal Neovascularization with Swept Source Optical Coherence Tomography Angiography (SS-OCTA) after Successful Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.Diagnostics (Basel, Switzerland) · 2023Article
- Photodynamic Therapy for Treatment of Disease in Children-A Review of the Literature.Children (Basel, Switzerland) · 2022Review
- Antimicrobial Photodynamic Coatings Reduce the Microbial Burden on Environmental Surfaces in Public Transportation-A Field Study in Buses.International journal of environmental research and public health · 2022Article
- Central Serous Chorioretinopathy Classification.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Bilateral multifocal and recurrent chorioretinopathy - case report.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central serous chorioretinopathy (CSC) is a common cause of visual impairment in patients generally aged 20 to 60 and it is characterized by acute or chronic neurosensory detachments of the retina. Although CSC resolves spontaneously in most cases, in some patients it may cause permanent visual impairment in the working population; for this reason, several approaches, including photodynamic therapy (PDT), subthreshold micropulse laser treatment and oral mineralocorticoid receptor antagonists, have been studied as first-line treatment options for CSC. To date, half-dose PDT has provided the most encouraging results in this regard, supported by large, multicenter, randomized clinical trials such as the "Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy" (PLACE) trial; however, the role of novel possible non-invasive treatment options is attracting interest. This review article aims to discuss the current pharmacological treatment options investigated for the management of CSC, including aspirin, ketoconazole, beta blockers, rifampicin and many others. In particular, further evidence about oral mineralocorticoid receptor antagonists, firstly seen as promising non-invasive alternatives for treating CSC, will be provided and discussed in light of the recent "Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months" (VICI) trial results, which have largely resized their role as possible first-line oral treatment options for treating CSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.